Telefon 0351 458 4233 | E-Mail | English

AG Linkermann

“Trying to prevent clinically relevant cell death“

Ever since Rudolf Virchow indicated necrosis as an uncontrollable clinical burden, the concept of necrosis as a non-regulated process evolved. However, today it is known that necrosis can result from genetically determined signalling pathways, and therefore represents a therapeutic target.

Virchow anticipated that necrosis is a central pathophysiological driver in countless detrimental diseases, such as stroke, myocardial infarction, sepsis, solid tumors, acute hemorrhage, pancreatitis, acute kidney injury, acute liver failure, trauma, rhabdomyolysis and toxicities, just to name the most relevant ones. Therefore, it has been a dream to prevent necrosis pharmacologically in clinical settings. And yes - we belive that this is possible!

Necrosis comes in different flavors, such as kinase-mediated necroptosis, caspase-mediated pyroptosis or lipoxygenase-mediated ferroptosis. Therefore, such enzymes represent novel therapeutic targets. Small molecules may be useful to prevent clinically relevant cell death. However, even larger molecules, such as phenytoin, may carry the potential to prevent clinically relevant necrosis. Click here for a 2017 overview on ferroptosis published in "Cell".


Prof. Dr. Andreas Linkermann
Principle Investigator
Tel.: +49 (0) 351 458-6629